Caregen (CEO Yongji Jeong) , a peptide-based biopharmaceutical company, announced on the 14th that it has signed a strategic partnership (MOU) with Indian pharmaceutical companies Torrent Pharmaceuticals (Torrent) and Micro Labs Limited (Microlabs). The agreement focuses on technology transfer and exclusive distribution cooperation for the company's key pipeline drugs, "Korglutide" and "Myoki."
This MOU is a follow-up to last month's agreement with Dr. Reddy's Laboratories, and Caregen is currently conducting strategic open negotiations (SORNs) with all three pharmaceutical companies. While the names of the participating companies will be disclosed, the specific terms remain confidential.
Coglutide is an oral dual-action peptide that simultaneously targets the GLP-1 receptor (GLP-1R) and IGF-1R. It is considered to offer ease of administration and price competitiveness compared to existing injectables. Myoki, through its anti-myostatin mechanism, complements the muscle-loss side effect that can occur with GLP-1 therapy.
India is a market where GLP-1-related treatments are expensive, lack of cold chain infrastructure, and low medication adherence are cited as challenges. Caregen's products are being evaluated as an alternative that can overcome these limitations. Notably, with the Food Safety and Standards Authority of India (FSSAI) expanding its Functional Food for Medical Use (FSDU) system, Caregen has already secured the relevant certification.
The three pharmaceutical companies each possess distinct market strengths. Dr. Reddy's is a leading pharmaceutical company in India with a global distribution network, while Torrent excels in the healthcare market, focusing on metabolic diseases. Microlabs boasts a wide range of pharmacies and online distribution channels in India, providing strong access to the consumer market.
Caregen emphasized its position as a technology supplier by adopting a strategic open negotiation approach in these negotiations. A company representative explained, "This negotiation is a case where we have simultaneously secured the credibility and market recognition of Caregen's technology."
Meanwhile, Caregen plans to participate in 'CPHI Worldwide 2025' held in Frankfurt, Germany and 'BIO Europe 2025' held in Vienna, Austria, where it also plans to present the interim results of the clinical trial of coglutide.
Caregen CEO Jeong Yong-ji said, “This agreement signifies that Caregen’s technology has been recognized for its competitiveness in the global market,” and added, “We will work to ensure that the technology transfer agreement is concluded as quickly as possible.”
- See more related articles
You must be logged in to post a comment.